Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 1:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–71 of 71 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: albuterol/salbutamol HFA Clear all
Terminated Phase 3 Interventional Results available

A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects

NCT02150499
View directory record Official record
Conditions
Asthma
Interventions
levalbuterol tartrate HFA inhalation aerosol, placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
Up to 48 Months
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
17
States / cities
St. Petersburg, Florida • DeKalb, Illinois • Nicholasville, Kentucky + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 9, 2026, 1:24 AM EDT
Active, not recruiting Phase 3 Interventional

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

NCT06473779
View directory record Official record
Conditions
Severe Asthma
Interventions
Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA®), Mannitol, Salbutamol
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Palmdale, California • Colorado Springs, Colorado • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 9, 2026, 1:24 AM EDT
Completed Phase 2 Interventional Results available

Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma

NCT03364608
View directory record Official record
Conditions
Asthma
Interventions
AS MDI 90 μg, AS MDI 180 µg, Placebo MDI, Proventil 90 μg, Proventil 180 μg
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Rolling Hills Estates, California • Stockton, California • Winter Park, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 9, 2026, 1:24 AM EDT
Completed Phase 2 Interventional

Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006

NCT01189396
View directory record Official record
Conditions
Asthma, Bronchospasm, Chronic Obstructive Pulmonary Disease (COPD)
Interventions
A006, Placebo DPI, Proventil-HFA
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Medford, Oregon • Portland, Oregon • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 9, 2026, 1:24 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects

NCT00909779
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Arformoterol, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
40 Years and older
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
73
States / cities
Birmingham, Alabama • Brimingham, Alabama • Jasper, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 9, 2026, 1:24 AM EDT
Recruiting Phase 4 Interventional

Ventilation and Perfusion in Asthmatics

NCT07426458
View directory record Official record
Conditions
Asthma
Interventions
Albuterol Sulfate, Albuterol-Budesonide
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 9, 2026, 1:24 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids

NCT01479621
View directory record Official record
Conditions
Asthma
Interventions
Fp MDPI, Flovent Diskus, albuterol/salbutamol, Placebo MDPI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
909 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
129
States / cities
Homewood, Alabama • Goodyear, Arizona • Scottsdale, Arizona + 104 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 9, 2026, 1:24 AM EDT
Completed Phase 2 Interventional Results available

Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Proventil as an Active Control in Subjects With Asthma

NCT03371459
View directory record Official record
Conditions
Asthma
Interventions
AS MDI, Proventil
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Winter Park, Florida • North Dartmouth, Massachusetts • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 9, 2026, 1:24 AM EDT
Completed Phase 2 Interventional Results available

4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma

NCT00818454
View directory record Official record
Conditions
Asthma
Interventions
Combivent CFC MDI, Albuterol HFA MDI, Respimat Combivent
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
41
States / cities
Birmingham, Alabama • Los Angeles, California • Palmdale, California + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 9, 2026, 1:24 AM EDT
Completed Phase 2 Interventional

Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma

NCT00096616
View directory record Official record
Conditions
Asthma
Interventions
Combivent® CFC MDI, Albuterol HFA MDI
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
27
States / cities
Birmingham, Alabama • Lakewood, California • Palmdale, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 9, 2026, 1:24 AM EDT
Completed Phase 3 Interventional Results available

Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE)

NCT00200967
View directory record Official record
Conditions
Asthma
Interventions
salmeterol, beclomethasone HFA
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
7
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 9, 2026, 1:24 AM EDT
Completed Phase 3 Interventional Results available

Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma

NCT02139644
View directory record Official record
Conditions
Asthma
Interventions
FS MDPI, Fp MDPI, Placebo MDPI, albuterol/salbutamol, Beclomethasone dipropionate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
76
States / cities
Birmingham, Alabama • Glendale, Arizona • Cypress, California + 64 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2021 · Synced Oct 9, 2026, 1:24 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma

NCT02040766
View directory record Official record
Conditions
Asthma
Interventions
Beclomethasone dipropionate BAI, Placebo BAI, albuterol/salbutamol 90 mcg, Beclomethasone dipropionate MDI, Placebo MDI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
75
States / cities
Hoover, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 9, 2026, 1:24 AM EDT
Withdrawn Phase 3 Interventional

Pharmacodynamic Bioequivalence Study of Albuterol Sulfate Inhalation Aerosol, 0.09 mg Albuterol Base/ Inhalation

NCT05292976
View directory record Official record
Conditions
Bronchial Asthma
Interventions
Methacholine Chloride, Albuterol Sulfate HFA 0.09 mg (Reference), Albuterol Sulfate HFA 0.18 mg (Reference), Albuterol Sulfate HFA 0.09 mg (Test), Albuterol Sulfate HFA 0.18 mg (Test), Placebo
Other · Drug
Lead sponsor
Aurobindo Pharma Ltd
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated May 20, 2022 · Synced Oct 9, 2026, 1:24 AM EDT
Completed Phase 4 Interventional Results available

Individualizing Treatment for Asthma in Primary Care

NCT06272370
View directory record Official record
Conditions
Asthma, Bronchial Diseases, Respiratory Tract Infections, Lung Diseases, Obstructive, Lung Diseases, Respiratory Hypersensitivity, Immune System Diseases
Interventions
Asthma Symptom Monitoring online tools, Inhaled Steroids, Azithromycin Pill
Other · Drug
Lead sponsor
DARTNet Institute
Government
Eligibility
12 Years to 75 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 9, 2026, 1:24 AM EDT
Completed No phase listed Observational

Examining the Link Between Obesity, Inflammation, and Response to Asthma Medications

NCT00557180
View directory record Official record
Conditions
Asthma, Obesity
Interventions
Beclomethasone dipropionate HFA, Tiotropium bromide, Salmeterol xinafoate
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 9, 2026, 1:24 AM EDT
Completed Phase 2 Interventional

A Safety and Tolerability Study of Levalbuterol HFA Metered Dose Inhaler in Subjects With Asthma

NCT00684827
View directory record Official record
Conditions
Asthma
Interventions
Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI, Racemic Albuterol followed by levalbuterol HFA MDI
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
4
States / cities
Encinitas, California • Los Angeles, California • North Dartmouth, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 9, 2026, 1:24 AM EDT
Completed Phase 2 Interventional

Comparative Effectiveness of a Breath-operated Albuterol Inhaler in Asthma Patients With Poor Inhaler Technique

NCT00054964
View directory record Official record
Conditions
Asthma
Interventions
Albuterol HFA-BOI, Albuterol HFA-MDI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 9, 2026, 1:24 AM EDT
Completed Phase 4 Interventional

Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma

NCT06563102
View directory record Official record
Conditions
Mild Asthma
Interventions
Albuterol/Budesonide, Albuterol
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
16
States / cities
Phoenix, Arizona • Tucson, Arizona • Lancaster, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 9, 2026, 1:24 AM EDT
Completed Phase 2 Interventional

Safety and Tolerability Study of Levalbuterol HFA Compared to Racemic Albuterol HFA in Subjects With Asthma

NCT00685022
View directory record Official record
Conditions
Asthma
Interventions
Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI, Racemic Albuterol followed by levalbuterol HFA MDI
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
3
States / cities
Encinitas, California • North Dartmouth, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 9, 2026, 1:24 AM EDT
Terminated Phase 3 Interventional

Single-Dose Cross-Over Study of the Effects of Albuterol-HFA in Exercise Induced Bronchoconstriction

NCT00634829
View directory record Official record
Conditions
Asthma, Bronchospasm
Interventions
albuterol (Armstrong Albuterol HFA), Albuterol Sulfate (Provenetil-HFA), Placebo-HFA
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Denver, Colorado • Englewood, Colorado • Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Oct 9, 2026, 1:24 AM EDT
Completed Phase 2 Interventional

Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol in Pediatric Subjects

NCT00685347
View directory record Official record
Conditions
Asthma, Bronchoconstriction
Interventions
Levalbuterol HFA MDI, Racemic Albuterol
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
6
States / cities
Long Beach, California • Denver, Colorado • Englewood, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 9, 2026, 1:24 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

NCT02175771
View directory record Official record
Conditions
Persistent Asthma
Interventions
Fp MDPI, FS MDPI, FLOVENT HFA, ADVAIR DISKUS, albuterol/salbutamol HFA
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
101
States / cities
Birmingham, Alabama • Mobile, Alabama • Pell City, Alabama + 85 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 9, 2026, 1:24 AM EDT